189 related articles for article (PubMed ID: 19931613)
1. Selective regulation of aromatase expression for drug discovery.
Brueggemeier RW; Su B; Darby MV; Sugimoto Y
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):207-10. PubMed ID: 19931613
[TBL] [Abstract][Full Text] [Related]
2. Aromatase and COX in breast cancer: enzyme inhibitors and beyond.
Brueggemeier RW; Su B; Sugimoto Y; Díaz-Cruz ES; Davis DD
J Steroid Biochem Mol Biol; 2007; 106(1-5):16-23. PubMed ID: 17616393
[TBL] [Abstract][Full Text] [Related]
3. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
Su B; Diaz-Cruz ES; Landini S; Brueggemeier RW
J Med Chem; 2006 Feb; 49(4):1413-9. PubMed ID: 16480277
[TBL] [Abstract][Full Text] [Related]
4. Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.
Su B; Tian R; Darby MV; Brueggemeier RW
J Med Chem; 2008 Mar; 51(5):1126-35. PubMed ID: 18271519
[TBL] [Abstract][Full Text] [Related]
5. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Brueggemeier RW; Díaz-Cruz ES; Li PK; Sugimoto Y; Lin YC; Shapiro CL
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):129-36. PubMed ID: 15964185
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
Su B; Landini S; Davis DD; Brueggemeier RW
J Med Chem; 2007 Apr; 50(7):1635-44. PubMed ID: 17315855
[TBL] [Abstract][Full Text] [Related]
7. Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.
Brueggemeier RW; Díaz-Cruz ES
Minerva Endocrinol; 2006 Mar; 31(1):13-26. PubMed ID: 16498361
[TBL] [Abstract][Full Text] [Related]
8. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition.
Su B; Díaz-Cruz ES; Landini S; Brueggemeier RW
Steroids; 2008 Jan; 73(1):104-11. PubMed ID: 18045633
[TBL] [Abstract][Full Text] [Related]
9. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.
Díaz-Cruz ES; Brueggemeier RW
Anticancer Agents Med Chem; 2006 May; 6(3):221-32. PubMed ID: 16712450
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.
Su B; Darby MV; Brueggemeier RW
J Comb Chem; 2008; 10(3):475-83. PubMed ID: 18380483
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.
Díaz-Cruz ES; Shapiro CL; Brueggemeier RW
J Clin Endocrinol Metab; 2005 May; 90(5):2563-70. PubMed ID: 15687328
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Prosperi JR; Robertson FM
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):55-70. PubMed ID: 16997132
[TBL] [Abstract][Full Text] [Related]
13. Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Su B; Chen S
Bioorg Med Chem Lett; 2009 Dec; 19(23):6733-5. PubMed ID: 19854050
[TBL] [Abstract][Full Text] [Related]
14. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Richards JA; Petrel TA; Brueggemeier RW
J Steroid Biochem Mol Biol; 2002 Feb; 80(2):203-12. PubMed ID: 11897504
[TBL] [Abstract][Full Text] [Related]
15. A positive feedback pathway of estrogen biosynthesis in breast cancer cells is contained by resveratrol.
Wang Y; Ye L; Leung LK
Toxicology; 2008 Jun; 248(2-3):130-5. PubMed ID: 18462857
[TBL] [Abstract][Full Text] [Related]
16. 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells.
Su B; Mershon SM; Stonerock LA; Curley RW; Brueggemeier RW
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):40-6. PubMed ID: 18248980
[TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
Su B; Cai X; Hong Y; Chen S
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):232-8. PubMed ID: 20542113
[TBL] [Abstract][Full Text] [Related]
18. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.
Krishnan AV; Swami S; Peng L; Wang J; Moreno J; Feldman D
Endocrinology; 2010 Jan; 151(1):32-42. PubMed ID: 19906814
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H
J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818
[TBL] [Abstract][Full Text] [Related]
20. Aromatase and cyclooxygenases: enzymes in breast cancer.
Brueggemeier RW; Richards JA; Petrel TA
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):501-7. PubMed ID: 14623550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
